<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274429</url>
  </required_header>
  <id_info>
    <org_study_id>11-2314</org_study_id>
    <nct_id>NCT01274429</nct_id>
  </id_info>
  <brief_title>Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults</brief_title>
  <official_title>Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to produce a new treatment that would benefit adult subjects by&#xD;
      lowering the risk of anaphylactic reactions (desensitization), and changing the&#xD;
      peanut-specific immune response in subjects who have peanut allergy (tolerance). This project&#xD;
      is designed to study the innovative idea that oral immunotherapy (OIT), the ingestion of&#xD;
      small increasing amounts of food allergen, will desensitize subjects with peanut&#xD;
      hypersensitivity by regulating their mucosal and systemic immune reactivity and cause&#xD;
      long-term tolerance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this proposal is to produce a new treatment that would benefit subjects who have&#xD;
      peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing&#xD;
      the peanut-specific immune response in subjects who have peanut allergy (tolerance). This is&#xD;
      a research study to test stimulation of the immune system to improve peanut allergy. The&#xD;
      approach the investigators will use for peanut allergy is called desensitization. A person&#xD;
      becomes desensitized to a food by taking small, increasing amounts of the food to help the&#xD;
      body become used to the food so that it no longer causes a severe allergic reaction.&#xD;
&#xD;
      The study also looks at the safety and immune system effects of the investigational study&#xD;
      product, peanut protein. The word &quot;investigational&quot; means the study product is still being&#xD;
      tested in research studies and is not approved by the U.S. Food and Drug Administration&#xD;
      (FDA).&#xD;
&#xD;
      This project is designed to study if peanut oral immunotherapy (POIT) will desensitize&#xD;
      subjects with peanut hypersensitivity by regulating their oral and systemic immune reactivity&#xD;
      and cause long-term tolerance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding&#xD;
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Whether This Peanut OIT Protocol Lowers Their Risk of Anaphylactic Reactions and Causes Long-term Tolerance.</measure>
    <time_frame>2-3 years</time_frame>
    <description>Assess mg of peanut tolerated on double-blind placebo-controlled food challenge as a measure of desensitization and tolerance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the Effect That PNOIT Has on the Peanut-specific Cellular and Humoral Response in Peanut-allergic Subjects.</measure>
    <time_frame>2-3 years</time_frame>
    <description>Measure changes over the course of treatment in serum specific IgE and IgG4, skin prick tests, TH1 and TH2 cytokines, and CD4+ CD25+ FoxP3+ regulatory T cells</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>Open label peanut flour</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peanut flour</intervention_name>
    <description>Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.</description>
    <arm_group_label>Open label peanut flour</arm_group_label>
    <other_name>Peanut OIT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 50 years of age of any gender, race, or ethnicity.&#xD;
&#xD;
          -  Diagnosis of peanut allergy OR convincing clinical history of peanut allergy.&#xD;
&#xD;
          -  Detectable serum peanut -specific Immune globin E(IgE) level (CAP-FEIA ≥ 0.35 kU/L)&#xD;
             and a positive skin prick test (SPT) to peanut.&#xD;
&#xD;
          -  Participant willing to use effective method of contraception if female for the&#xD;
             duration of the study, not pregnant or lactating, and not planning to become pregnant.&#xD;
&#xD;
          -  Positive reaction to ≤ 2 gm peanut protein on entry challenge.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe anaphylaxis to peanut per current National Cancer Institute Common&#xD;
             Toxicity Criteria for Adverse Effects (NCI-CTCAE) allergic reaction toxicity grading.&#xD;
&#xD;
          -  Known sensitivity or intolerance to Oats.&#xD;
&#xD;
          -  FEV1 value &lt;80% predicted or any clinical features of moderate or persistent asthma&#xD;
             per 2007 National Heart Lung and Blood Institute (NHLBI) guidelines.&#xD;
&#xD;
          -  Exacerbation of asthma in the past year requiring hospitalization or greater than 1&#xD;
             emergency department (ED) visit for asthma in the past 6 months.&#xD;
&#xD;
          -  Use Beta-blockers, ACE inhibitors, angiotensin receptor blocker (ARB) , or calcium&#xD;
             channel blockers, xolair, or immunological treatments.&#xD;
&#xD;
          -  Uncontrolled hypertension per JNC 7 Guidelines (BP &gt; 145/95 seated readings on each of&#xD;
             two or more office visits).&#xD;
&#xD;
          -  Active eosinophilic gastrointestinal disease which could be exacerbated by peanut oral&#xD;
             immunotherapy.&#xD;
&#xD;
          -  Chronic diseases such as diabetes, liver, gastrointestinal, kidney, cardiovascular,&#xD;
             pulmonary disease, blood disorders, or history of ischemic cardiovascular disease, or&#xD;
             other conditions that in the opinion of the Investigator make the subject unsuitable&#xD;
             for induction of food allergy reactions.&#xD;
&#xD;
          -  Unable to speak English.&#xD;
&#xD;
          -  Inability to discontinue antihistamines prior to food challenges and skin prick tests.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wesley Burks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>January 9, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <results_first_submitted>January 21, 2017</results_first_submitted>
  <results_first_submitted_qc>January 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2017</results_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peanut allergy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>OIT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Open Label Peanut Flour</title>
          <description>Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study closed do to lack of funding</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label Peanut Flour</title>
          <description>Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.&#xD;
Peanut flour: Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.5" lower_limit="18.8" upper_limit="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine Whether This Peanut OIT Protocol Lowers Their Risk of Anaphylactic Reactions and Causes Long-term Tolerance.</title>
        <description>Assess mg of peanut tolerated on double-blind placebo-controlled food challenge as a measure of desensitization and tolerance</description>
        <time_frame>2-3 years</time_frame>
        <population>No subjects reached the end of study food challenge prior to closure of the study and therefore no data was collected towards this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Peanut Flour</title>
            <description>Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Determine Whether This Peanut OIT Protocol Lowers Their Risk of Anaphylactic Reactions and Causes Long-term Tolerance.</title>
          <description>Assess mg of peanut tolerated on double-blind placebo-controlled food challenge as a measure of desensitization and tolerance</description>
          <population>No subjects reached the end of study food challenge prior to closure of the study and therefore no data was collected towards this endpoint.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Effect That PNOIT Has on the Peanut-specific Cellular and Humoral Response in Peanut-allergic Subjects.</title>
        <description>Measure changes over the course of treatment in serum specific IgE and IgG4, skin prick tests, TH1 and TH2 cytokines, and CD4+ CD25+ FoxP3+ regulatory T cells</description>
        <time_frame>2-3 years</time_frame>
        <population>No subjects reached the end of study prior to closure of the study and therefore no end of treatment mechanistic data was collected in order to compare against the baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Peanut Flour</title>
            <description>Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Effect That PNOIT Has on the Peanut-specific Cellular and Humoral Response in Peanut-allergic Subjects.</title>
          <description>Measure changes over the course of treatment in serum specific IgE and IgG4, skin prick tests, TH1 and TH2 cytokines, and CD4+ CD25+ FoxP3+ regulatory T cells</description>
          <population>No subjects reached the end of study prior to closure of the study and therefore no end of treatment mechanistic data was collected in order to compare against the baseline.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2.5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Open Label Peanut Flour</title>
          <description>Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye itch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Eye tearing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oropharyngeal itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nose itch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythematous rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin itch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lip or eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to lack of funding prior to any subjects reaching the primary endpoint.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Edwin Kim, Director of the UNC Food Allergy Initiative</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-843-9087</phone>
      <email>edwinkim@email.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

